Literature DB >> 21762186

Clinical features and natural history of hepatocellular adenomas: the impact of obesity.

C Bunchorntavakul1, R Bahirwani, D Drazek, M C Soulen, E S Siegelman, E E Furth, K Olthoff, A Shaked, K R Reddy.   

Abstract

BACKGROUND: Hepatocellular adenoma is a benign tumour associated with bleeding and malignant transformation. Obesity has been linked to hepatic tumourigenesis. AIM: To evaluate the presentation of hepatocellular adenoma in obesity, and the impact of obesity on the clinical course.
METHODS: Records of 60 consecutive patients (between 2005 and 2010) with a diagnosis of hepatocellular adenoma from a single tertiary centre were analysed.
RESULTS: Fifty six of 60 patients were women, median age was 36years, 75% had history of contraceptive use, 18% were overweight and 55% were obese (BMI ≥30kg/m(2) ). Majority (63%) were asymptomatic; seven patients presented with bleeding. Single (28%) and multiple adenomas (72%) were encountered; size ranged from 1 to 19.7cm. Obesity was more often associated with multiple adenomas (85% vs. 48%, P=0.005), bilobar distribution (67% vs. 33%, P=0.01), lower serum albumin (P=0.007) and co-morbidities of fatty liver (P=0.006), diabetes (P=0.003), hypertension (P=0.006) and dyslipidemia (P=0.03). During median follow-up of 2.6years, there were no instances of bleeding, malignant transformation or death. Thirty four patients underwent therapeutic intervention (17 surgical resection, nine transarterial embolization and eight both interventions sequentially). The rate of complete resection of adenoma(s) was significantly lower in obese patients (8% vs. 69%, P=0.004). In the 26 patients without intervention, tumour size progression was more frequently observed in obese patients (33% vs. 0%, P=0.05). Three of 15 obese patients (20%) lost ≥5% body weight and there was no progression in the liver lesions.
CONCLUSIONS: Obesity and features of metabolic syndrome were frequently observed in hepatocellular adenoma. Multiple and bilobar adenomas were more frequent in obese patients. Among patients who were conservatively managed, tumour progression was more often associated with obesity.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21762186     DOI: 10.1111/j.1365-2036.2011.04772.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

Review 1.  Hepatocellular adenoma management: advances but still a long way to go.

Authors:  Jean Frédéric Blanc; Nora Frulio; Laurence Chiche; Paulette Bioulac-Sage; Charles Balabaud
Journal:  Hepat Oncol       Date:  2015-05-15

2.  Treatment of Hepatic Adenomatosis.

Authors:  Claire Meyer; Mauricio Lisker-Melman
Journal:  Curr Hepatol Rep       Date:  2015-05-02

Review 3.  Management of hepatic adenomatosis.

Authors:  Manish Thapar; Oleg Grapp; Constantine Fisher
Journal:  Curr Gastroenterol Rep       Date:  2015-03

Review 4.  Liver masses: a clinical, radiologic, and pathologic perspective.

Authors:  Sudhakar K Venkatesh; Vishal Chandan; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-18       Impact factor: 11.382

5.  Imaging Surveillance of Hypervascular Liver Lesions in Non-Cirrhotic Patients.

Authors:  Yun Shin Chun; Robin J Parker; Subbarao Inampudi; Eduardo Ehrenwald; Kenneth P Batts; Lawrence J Burgart; Clark W Schumacher; Jason A Mehling; Bjorn I Engstrom; Mark J Hill; Srinevas K Reddy; Timothy D Sielaff
Journal:  J Gastrointest Surg       Date:  2015-09-16       Impact factor: 3.452

6.  European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group.

Authors:  Alexis Laurent; Safi Dokmak; Jean-Charles Nault; François-René Pruvot; Jean-Michel Fabre; Christian Letoublon; Philippe Bachellier; Lorenzo Capussotti; Olivier Farges; Jean-Yves Mabrut; Yves-Patrice Le Treut; Ahmet Ayav; Bertrand Suc; Olivier Soubrane; Gilles Mentha; Irinel Popescu; Marco Montorsi; Nicolas Demartines; Jacques Belghiti; Guido Torzilli; Daniel Cherqui; Jean Hardwigsen
Journal:  HPB (Oxford)       Date:  2016-07-22       Impact factor: 3.647

Review 7.  Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?

Authors:  Giovanni Targher; Maurizio Rossini; Amedeo Lonardo
Journal:  Endocrine       Date:  2015-05-30       Impact factor: 3.633

8.  Management of hepatocellular adenoma: comparison of resection, embolization and observation.

Authors:  Ami M Karkar; Laura H Tang; Nilesh D Kashikar; Mithat Gonen; Stephen B Solomon; Ronald P Dematteo; Michael I D' Angelica; Camilo Correa-Gallego; William R Jarnagin; Yuman Fong; George I Getrajdman; Peter Allen; T Peter Kingham
Journal:  HPB (Oxford)       Date:  2012-10-09       Impact factor: 3.647

9.  Hepatocellular adenoma in a woman who was undergoing testosterone treatment for gender identity disorder.

Authors:  Keizo Kato; Hiroshi Abe; Noriko Hanawa; Junya Fukuzawa; Ryota Matsuo; Takeshi Yonezawa; Sadahiro Itoh; Yoshiyuki Sato; Makiko Ika; Shohei Shimizu; Shinji Endo; Hiroshi Hano; Asami Izu; Masahiko Sugitani; Akihito Tsubota
Journal:  Clin J Gastroenterol       Date:  2018-03-27

Review 10.  Current Approaches in the Management of Hepatic Adenomas.

Authors:  Diamantis I Tsilimigras; Amir A Rahnemai-Azar; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Demetrios Moris; Eleftherios Spartalis; Jordan M Cloyd; Sharon M Weber; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-08-14       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.